Compile Data Set for Download or QSAR
maximum 50k data
Found 22 of ic50 for monomerid = 111122
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  29nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  29nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  40nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  40nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  83nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  83nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  112nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  112nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  146nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  146nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  229nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  229nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  864nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  864nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  2.25E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  2.25E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  6.49E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  6.49E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  2.06E+4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  2.06E+4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  2.70E+4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  2.70E+4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent